Prevention of the development and progression of renal disease

被引:43
作者
Hostetter, TH [1 ]
机构
[1] NIDDKD, Natl Kidney Dis Educ Program, NIH, Div Kidney Urol & Hematol Dis, Bethesda, MD 20892 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷 / 07期
关键词
D O I
10.1097/01.ASN.0000070150.60928.06
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Prevention of the major causes of ESRD, hypertension, and diabetes, is possible. Careful glycemic control can prevent diabetes nephropathy. BP control can likely prevent the large majority of hypertensive renal disease. Testing for diabetic renal disease is well founded. In contrast, screening for hypertensive kidney disease is less well defined. Most established renal disease can be treated with glycemic control in the case of diabetes, BP treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and dietary protein restriction. Other therapeutic targets have been proposed, but are not well established. Future research should focus on defining the high risk patients, developing better markers of risk, and designing additional therapies.
引用
收藏
页码:S144 / S147
页数:4
相关论文
共 23 条
[1]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[2]  
*AM DIAB ASS, 2002, DIABETES CARE S1, V25, P71
[3]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[4]   The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors [J].
Golan, L ;
Birkmeyer, JD ;
Welch, HG .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (09) :660-+
[5]  
Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542
[6]   Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - A meta-analysis of patient-level data [J].
Jafar, TH ;
Schmid, CH ;
Landa, M ;
Giatras, I ;
Toto, R ;
Remuzzi, G ;
Maschio, G ;
Brenner, BM ;
Kamper, A ;
Zucchelli, P ;
Becker, G ;
Himmelmann, A ;
Bannister, K ;
Landais, P ;
Shahinfar, S ;
de Jong, PE ;
de Zeeuw, D ;
Lau, J ;
Levey, AS .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (02) :73-87
[7]  
*JOINT NAT COMM PR, 2003, NIH PUBL
[8]   The kidney in cardiovascular disease [J].
Kasiske, BI .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :707-709
[9]   A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function [J].
Kasiske, BL ;
Lakatua, JDA ;
Ma, JZ ;
Louis, TA .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (06) :954-961
[10]   Blood pressure and end-stage renal disease in men [J].
Klag, MJ ;
Whelton, PK ;
Randall, BL ;
Neaton, JD ;
Brancati, FL ;
Ford, CE ;
Shulman, NB ;
Stamler, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :13-18